Optimizing Care Delivery to Support Reengagement in PLWH Returning to HIV Care After Treatment Lapses in Zambia (Reengagement)

1.0 Introduction

The scale-up of human immunodeficiency virus (HIV) treatment services has expanded rapidly in Zambia, facilitated by evolution of the HIV response from centralized services to decentralized care and now towards differentiated service delivery models. Nevertheless, optimal effectiveness remains elusive because timely engagement in care to allow uninterrupted access to antiretroviral therapy (ART) and sustained viral suppression remain incomplete. Ensuring retention in care is especially relevant since greater numbers of HIV-infected patients are also entering a phase of long-term follow-up. After receiving access to HIV care, a high fraction become lost to follow up with some estimates as high as 25-40%, which is defined as the outcome where the patient has missed their appointment by 30 days and has not died or seeking care at a different healthcare facility, or disengaged from care altogether. Research also suggests that LTFU outcomes are driven by a multitude of factors including structural and clinic-based barriers, individual and community-based barriers. A new generation of innovative interventions is needed to overcome these multifaceted barriers to optimization of the engagement of HIV infected patients with the public health systems that have emerged to serve them. Sustained retention is a critical determinant of viral suppression for PLWH, but treatment interruptions put them at high risk for viremia and mortality.

Emerging evidence clearly demonstrates that people living with HIV (PLWH) frequently transition in and out of care over time in sub-Saharan Africa and the time of re-engagement in HIV care presents a critical opportunity to break these ongoing cycles of disengagement. Since the presence of specific barriers leads to disengagement from care for some patients, designing strategies targeting these barriers can offer up a natural prospect for ensuring long-term care engagement. It is evident that the strategies required to initiate a patient into care would be markedly different than those to ensure reengagement in care. Even when PLWH return to care after loss to follow-up (LTFU), rates of repeat LTFU in the future are very high. Our preliminary data from Zambia suggests that 30% become LTFU again within 6 months of return, and that 50% of those who are currently LTFU have previously cycled in and out of care. Few interventions have successfully improved return rates among those LTFU but an estimated 50-70% return to care on their own by one year. Strategies for intervening at the time of reengagement in care are urgently needed to break these cycles of disengagement in this high-risk population.

To address these knowledge gaps, we seek to engage key stakeholders in developing a reengagement program to address critical barriers to reengagement and strengthen long-term reengagement in care. This reengagement study will provide important direction for future interventions and studies to formally test this health-system intervention for patients reengaging in HIV care after LTFU.

1.1 Rationale

Evidence from our groups as well as throughout Africa highlight the critical needs to strengthen programs for reengagement into HIV care. It is well documented that PLWH frequently transition in and out of care over time in sub-Saharan Africa leading to treatment interruptions that can put them at high risk for viremia and mortality. Among those who return to care after loss to follow-up (LTFU), rates of repeat LTFU in the future are also very high with up to 30% becoming LTFU again within 6 months of return. Additionally, among those who are currently LTFU, 50% have previously cycled in and out of care indicating missed opportunities to intervene. As an estimated 50-70% of those LTFU return to care on their own by one year strategies for intervening at the time of reengagement in care are very promising to help break these cycles of disengagement in this high-risk population.

1.2 Research Question

What are the most important needs and preferences of patients and providers for a multicomponent reengagement strategy?

2.0 Study Objectives

2.1 Study Specific Aim

To develop a reengagement strategy that meets the needs and preferences of patients and providers in public health HIV settings.

2.2 Scientific Objectives

The study has three main objectives. These include:

1. Assess patient and provider needs and preferences for reengagement strategies using best-worse scaling experiments.
2. Assess patient and provider needs and preferences for reengagement strategies using qualitative methods.
3. Develop an intervention to optimize the experience of reengagement in HIV care using human-centered design.

Study Overview

• Status: Completed
• Conditions: HIV Antiretroviral Therapy (ART) Adherence

Detailed Description

Purpose of the research: To systematically evaluate the overall patient experience and its effect on retention in care and virologic suppression via multiple novel measurement modalities in public ART clinics in Zambia and make public health HIV treatment more patient centred, manage and enhance perceptions of quality, and strengthen engagement to optimize treatment.

Statement of the problem: Evidence from our previous Betterinfo study (004-06-14) as well as throughout sub-Saharan Africa points to patient experience as a crucial area for improvement. These data offer a simple synthesis and strategy for improvements. That is, when patients perceive encounters with the health system to be high-quality, respectful, accessible, responsive, and effective, engagement is strengthened.

Rationale/Justification for the study: This study will provide important direction for future interventions to implement more patient-centred care in the current public health HIV infrastructure, as it will fill important knowledge gaps regarding clinic-based barriers to care.

Research questions:

1. What are the most important needs and preferences of patients and providers for a multicomponent reengagement strategy?

Main Aim: To develop a reengagement strategy that meets the needs and preferences of patients and providers in public health HIV settings.

Specific objectives: The study has three main objectives. These include:

1. Assess patient and provider needs and preferences for reengagement strategies using best-worse scaling experiments.
2. Assess patient and provider needs and preferences for reengagement strategies using qualitative methods.
3. Develop an intervention to optimize the experience of reengagement in HIV care using human-centered design.

Methodology (design, sampling, data collection methods and tools):

Objective 1: Investigators will conduct best-worse scaling experiments among patients (n=400) and HCWs (n=200) to quantify relative preferences for the contents and implementation attributes for strategies to improve post-return care delivery.

Objective 2: Guided by the Consolidated Framework for Implementation Research and the Socioecological Model, investigators will use qualitative methods to explore how to optimize the experiences of care delivery after returning to HIV care. Investigators will conduct semi-structured interviews with PLWH who reengaged in the past 6 months and did (n=15) and did not (n=15) remain in care as well as focus group discussions with HCWs (i.e., physicians, nurses, clinic leadership; 6 FGDs, n=8-10 each)

Objective 3: Using principles from human-centered design and intervention mapping, investigators will synthesize findings from Aim 1 and co-develop a multicomponent reengagement coordination implementation strategy focused on:

1. improving the patient experience of reengagement,
2. optimizing ART re-initiation and viral load monitoring post-return, and
3. offering services tailored to initial LTFU reasons to support sustained engagement.

Investigators will employ an iterative human-centered process involving key stakeholders (reengaged PLWH, HCWs, clinic leadership, Ministry of Health) to co-design the key components (e.g., practice facilitation and audit-feedback for providers, tailored services for patients) and develop a locally appropriate and acceptable intervention prototype.

Data management issues (data management plan, analysis and storage):

Objective 1: Investigators will summarize routine survey responses using frequency and proportions. Investigators will evaluate the BWS exercise using count analysis and BWS scores for individuals (difference in number of times item scored best and worst/number of times item appears) and, aggregate score for the population (mean population score f rescaled to 100, presented as forest plots). Investigators will use standard statistical techniques to explore preference heterogeneity and will perform subgroups analyses across characteristics including reason for initial LTFU (i.e., structural, clinic-based, psychosocial), sex, age, and HCW cadre. Data will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Data will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Once data are linked to SmartCare records using ART numbers, identifying information will be removed in order to maintain confidentiality.

Objective 2: Recordings will be transcribed by trained CIDRZ RAs, and if necessary, translated into English with subsequent back translation or a second-party review of sections of the translation. With the transcribed audio-recording data, investigators will code and computerize for analysis. The audio recordings, data collection tools and memos will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Identifying information will be removed during transcription in order to maintain confidentiality. Transcriptions will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Investigators will use thematic content analysis across all data to analyze the data using qualitative software (e.g. Dedoose or NVivo). Qualitative data analysis consists of searching for patterns in data and conceptualizing ideas that help explain the presence of those patterns. For patient interviews, investigators will also employ a narrative analysis where we read each interview as a whole, without regard to individual codes, to create a more global understanding of the "point of the story".

Objective 3: Implementation of HCD generally follows an iterative framework of inquiry, problem-solving and co-design. Diverse methods are employed in each of these phases including system/stakeholder mapping, compiling secondary data, user journey maps/personas, cognitive sorting and ranking, and iterative prototyping. Investigators will collect detailed meeting minutes, visual outputs created from participatory activities, written reflections from participants, and take careful notes during the design team meetings and workshops. Investigators will qualitatively analyze data gathered during the HCD co-creation activities using affinity mapping and rapid thematic analysis. This will occur in between co-creation workshops to identify design opportunities to discuss in future workshops and also after the close of the final workshop.

Participants to be recruited and inclusion criteria: This study will be conducted in Lusaka province at four Ministry of Health-operated facilities that are supported by the Centre for Infectious Disease Research in Zambia (CIDRZ). All participants must give consent to participate. Additional inclusion criteria, sampling and sample size are as follows:

Objective 1 PLHW reengaging in HIV care: Investigators will enroll up to 400 PLWH (age≥18 years) who are reengaging in care from four health care facilities supported by CIDRZ in Lusaka. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 60 days late to their last appointment per Zambian HIV guidelines. Investigators will include PLWH returning to their original clinic or as a transfer from a different facility. Investigators will recruit participants on the day of return to care using similar recruitment procedures as Objective 1. Eligible participants will be identified by clinical staff during their routine clinic visit, and trained CIDRZ research assistants (RAs) will then recruit and enroll them in a private area as they wait for their clinical consultation or drug pick-up. Investigators have used this approach to successfully recruit over 300 returning patients to date as part of an ongoing study (BMFG OPP1166485).

Healthcare Workers: Investigators will enroll up to 200 health care workers who participate in the care of PLWH across these four health care facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. Investigators will use convenience sampling to identify HCW for surveys using procedures that have been well-established by our study team in Zambia to successfully recruit HCWs. Investigators will first engage with clinic leadership to identify appropriate times for recruitment and survey administration.

Objective 2 Patient Semi-Structured Interviews: Investigators will recruit PLWH (age≥18 years) who reengaged in care within the past 6 months at four health care facilities supported by CIDRZ in Lusaka and subsequently did (n=15) and did not (n=15) remain in care. Investigators will recruit individuals amongst our survey cohort who agreed to be contacted in the future for qualitative interviews. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 60 days late to their last appointment per Zambian HIV guidelines. Investigators will include PLWH returning to their original clinic or as a transfer from a different facility. Investigators will use purposive and maximum variation sampling of participants to ensure participants represent a range of perspectives (i.e., we will recruit participants based on patient characteristics such as gender and age to ensure a range of perspectives as well as barriers to care identified during surveys in Objective 1).

Eligible participants who remained in care will be identified by clinical staff during their routine clinic visit, and trained CIDRZ research assistants (RAs) will then recruit and enroll them in a private area. Those who become LTFU within 6-months of return will be identified in the EHR, through clinic logs, and through routine tracing procedures already in place. These individuals will be contacted via phone and recruited; if they agree to participate, they will then be interviewed in-person in mutually agreed private location. Our research team and CIDRZ has previously used these procedures to recruit LTFU participants for in-depth interviews.

Healthcare workers: The target population for this objective are all health care workers delivery HIV care at our study facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. Investigators will use convenience sampling to identify HCW for focus groups discussions among HCWs (i.e., clinicians, nurses, lay HCWs, pharmacists, clinic leadership) at four facilities. Investigators will use procedures that have been well-established by our study team in Zambia to successfully recruit HCWs. Investigators will first engage with clinic leadership to identify appropriate times for recruitment and interviews. Investigators will conduct 6 FGDs (N=8-10 each), which will be organized by HCW cadre to ensure that there is open discussion with minimal concern for power hierarchies.

Objective 3 Investigators will recruit reengaged patients (beneficiaries) and HCWs (implementers). Informed by Aim 1 findings, investigators will also use stakeholder mapping to identify key groups who may influence reengagement behaviors and outcomes among PLWH and HCWs and purposefully recruit from these groups from the four facilities in Aim 1. A priori, we expect to engage with patients who have reengaged in care (n=5-10), health care workers (n=5-10) (as beneficiaries and implementers, respectively, of the interventions) and clinic leadership (n=5) and Ministry of Health administrators (n=1-2) as influencers. Our team has experience recruiting and engaging these multilevel stakeholders in HCD workshops82. Recruitment will be similar to procedures outlined in previous objectives. Participants will be given K100 for travel reimbursement.

Ethical considerations: Investigators will submit the proposed protocol, the informed consent documents, data collection tools and any subsequent modifications for review and approval. Also, the Washington University School of Medicine (WUSM) Institutional Review Board (IRB) will provide ethical reviews and regulatory oversight through a reliance agreement with the other collaborating US institutions. Investigators request an expedited review and will obtain written informed consent from participants agreeing to participate in the following study activities:

• Patient Surveys and In-depth Interviews with patients.
• Health care worker surveys and Focus group discussions

Permission will be sought from national, provincial, district and facility Ministry of Health authorities to conduct the study in public health facilities. The study will follow standard Ministry of Health guidelines to engage with staff, patients and patient records. Investigators will also ensure that all staff involved with study data are trained in Good Clinical Practice and Human Subjects Protection.

Timelines: The study proposes to implement the study intervention over a course of 18 months. Detailed timeline with activities are outlined in the proposed protocol.

Plans to disseminate research findings:

In-order to maximise the benefit of the study findings without delay, the study findings will be shared with key stakeholders such as Ministry of Health and community leaders. Study findings will be disseminated at national, international meetings, conferences and in scientific journals. Permission will be sought from National Health Research Authority prior to any publications or any form of dissemination being made.

POSSIBLE BENEFITS TO PARTICIPANTS:

No direct benefits to participants are expected. Participants may benefit in that the aim provides a direct outlet for their input to be translated into intervention design and future policy decisions. Participants may benefit from improvements in quality of care provided and increased understanding from health care workers resulting from this work. Those disengaged from care may benefit from tracing and follow up by trained counsellors and may decide to re-engage in care. Participants will also receive a small reimbursement (approximately K 100) for their transport and time spent to participate in semi-structured interviews or FGDs. Health care workers and facilities may benefit from understanding patient expectations and from learning how data can be used to interpret and improve clinic practices. Patients may also benefit from the knowledge that their perspectives are valued for improving care delivery. The Zambian Ministry of Health will benefit from the coaching provided by the research team, which may serve to improve the working environment for health care workers and care delivered to patients. The HCD process will result in developing a reengagement strategy that can improve the care of people living with HIV.

POSSIBLE RISKS TO PARTICIPANTS:

All interviews and discussion have the potential to make participants embarrassed, worried, anxious, or uncomfortable when reporting on their interactions. Participants may feel uncomfortable answering questions or discussing their HIV treatment history with the research team during semi-structured interviews or when completed surveys. The research staff will be trained to be sensitive to these areas, for example, such as discussing challenges with HIV care, livelihoods, or family. HCWs may similarly experience discomfort discussing or answering surveys pertinent to their own skills or work preferences. Some participants who are currently lost from care may be contacted via telephone to participate in interviews. This contact may have a small possible risk of involuntary disclosure of HIV status. Investigators will attempt to minimize this by training all follow up staff to be discrete and professional, ensuring that patient confidentiality is maintained at all times and identities are verified prior to providing additional information.

During FGDs, colleagues may also be present and HCWs may fear reprisal if confidentiality is breached. FGDs will be organized by HCW cadre to be sensitive of power dynamics and ensure comfort in openly discussing pertinent topics.

Participants in HCD workshops may also feel uncomfortable answering questions and participating in discussions regarding the challenges about receiving and/or delivering HIV care. Patients may fear negative attitudes from HCWs and HCWs may worry about retribution from their superiors. Workshop composition will be attentive to power dynamics, ensuring participants are engaged on days of the workshop or through sub-groups such that they are free to share their opinions and act as co-designers (e.g., patients or HCWs feel free to share thoughts in presence of health care administrators).

Details of how these risks will be minimized are outlined in the protocol.

POSSIBLE BENEFITS TO THE COMMUNITY:

The potential benefits to society may be an increased understanding of how the process of reengagement can be improved to facilitate ongoing sustained engagement in care and overall HIV outcomes and the needs and preferences of key stakeholders.

• Study Type: Observational
• Enrollment (Actual): 658

Contacts and Locations

Study Locations

• Zambia
  • Lusaka Province
    • Lusaka, Lusaka Province, Zambia, 10101
      • Centre for Infectious Disease Research in Zambia (CIDRZ)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patient Semi-Structured Interviews: We will recruit PLWH (age≥18 years) who reengaged in care within the past 6 months at four health care facilities supported by CIDRZ in Lusaka and subsequently did (n=15) and did not (n=15) remain in care. We will recruit individuals amongst our survey cohort who agreed to be contacted in the future for qualitative interviews. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 30 days late to their last appointment per Zambian HIV guidelines and or not having ART drugs for greater than 30 days.

Healthcare workers: The target population for this objective are all health care workers involved in delivery HIV care at our study facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. We use convenience sampling to identify HCW for in-depth interviews (IDIs) (i.e., clinicians, nurses,

Description

Inclusion Criteria:

• Participant must be over 18 years of age.
• Should be LTFU for greater than 30 days or
• Should not have had ART drugs for greater than 30 days;
• Pregnant women who meet inclusion criteria
• Illiterate participants willing to provide informed consent in Nyanja or Bemba provided there is a witness.

Exclusion Criteria:

• Participant is too sick i.e., failing to talk, general discomfort and emergency cases).
• Participant is unable to provide written informed consent in English, Nyanja or Bemba.
• Participant who is drunk or mentally ill.

Exclusion Criteria:

-

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Retention	Number of participants who reengaged (less than 30 days late to their scheduled appointments) and were consistently taking their medication	2022 to 2025

Collaborators and Investigators

• Sponsor: Centre for Infectious Disease Research in Zambia
• Collaborators: National Institute of Mental Health (NIMH); Washington University School of Medicine
• Investigators: Principal Investigator: Izukanji Sikazwe, Medical Officer, Centre for Infectious Disease Research in Zambia

Publications and helpful links

General Publications

• Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.
• Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Health. 2015 Sep;42(5):533-44. doi: 10.1007/s10488-013-0528-y.
• Haberer JE, Sabin L, Amico KR, Orrell C, Galarraga O, Tsai AC, Vreeman RC, Wilson I, Sam-Agudu NA, Blaschke TF, Vrijens B, Mellins CA, Remien RH, Weiser SD, Lowenthal E, Stirratt MJ, Sow PS, Thomas B, Ford N, Mills E, Lester R, Nachega JB, Bwana BM, Ssewamala F, Mbuagbaw L, Munderi P, Geng E, Bangsberg DR. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. J Int AIDS Soc. 2017 Mar 22;20(1):21371. doi: 10.7448/IAS.20.1.21371. eCollection 2017.
• Higginbottom GM. Sampling issues in qualitative research. Nurse Res. 2004;12(1):7-19. doi: 10.7748/nr2004.07.12.1.7.c5927.
• Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007 Oct 24;298(16):1888-99. doi: 10.1001/jama.298.16.1888.
• Bate P, Robert G. Experience-based design: from redesigning the system around the patient to co-designing services with the patient. Qual Saf Health Care. 2006 Oct;15(5):307-10. doi: 10.1136/qshc.2005.016527.
• Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, Flash MJ, Govender T, Walensky RP, Freedberg KA, Losina E. Barriers to Care and 1-Year Mortality Among Newly Diagnosed HIV-Infected People in Durban, South Africa. J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):432-438. doi: 10.1097/QAI.0000000000001277.
• Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006 Aug 16;296(7):782-93. doi: 10.1001/jama.296.7.782.
• Means AR, Kemp CG, Gwayi-Chore MC, Gimbel S, Soi C, Sherr K, Wagenaar BH, Wasserheit JN, Weiner BJ. Evaluating and optimizing the consolidated framework for implementation research (CFIR) for use in low- and middle-income countries: a systematic review. Implement Sci. 2020 Mar 12;15(1):17. doi: 10.1186/s13012-020-0977-0.
• Lyon AR, Munson SA, Renn BN, Atkins DC, Pullmann MD, Friedman E, Arean PA. Use of Human-Centered Design to Improve Implementation of Evidence-Based Psychotherapies in Low-Resource Communities: Protocol for Studies Applying a Framework to Assess Usability . JMIR Res Protoc. 2019 Oct 9;8(10):e14990. doi: 10.2196/14990.
• Ehrenkranz P, Rosen S, Boulle A, Eaton JW, Ford N, Fox MP, Grimsrud A, Rice BD, Sikazwe I, Holmes CB. The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals. PLoS Med. 2021 May 24;18(5):e1003651. doi: 10.1371/journal.pmed.1003651. eCollection 2021 May.
• Vindrola-Padros C, Johnson GA. Rapid Techniques in Qualitative Research: A Critical Review of the Literature. Qual Health Res. 2020 Aug;30(10):1596-1604. doi: 10.1177/1049732320921835.
• Beres LK, Simbeza S, Holmes CB, Mwamba C, Mukamba N, Sharma A, Munamunungu V, Mwachande M, Sikombe K, Bolton Moore C, Mody A, Koyuncu A, Christopoulos K, Jere L, Pry J, Ehrenkranz PD, Budden A, Geng E, Sikazwe I. Human-Centered Design Lessons for Implementation Science: Improving the Implementation of a Patient-Centered Care Intervention. J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3(3):S230-S243. doi: 10.1097/QAI.0000000000002216.
• Koenig CJ, Abraham T, Zamora KA, Hill C, Kelly PA, Uddo M, Hamilton M, Pyne JM, Seal KH. Pre-Implementation Strategies to Adapt and Implement a Veteran Peer Coaching Intervention to Improve Mental Health Treatment Engagement Among Rural Veterans. J Rural Health. 2016 Sep;32(4):418-428. doi: 10.1111/jrh.12201. Epub 2016 Aug 10.
• Roy M, Holmes C, Sikazwe I, Savory T, Mwanza MW, Bolton Moore C, Mulenga K, Czaicki N, Glidden DV, Padian N, Geng E. Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia. Clin Infect Dis. 2018 Sep 28;67(8):1269-1277. doi: 10.1093/cid/ciy285.
• Holmes CB, Sikazwe I, Sikombe K, Eshun-Wilson I, Czaicki N, Beres LK, Mukamba N, Simbeza S, Bolton Moore C, Hantuba C, Mwaba P, Phiri C, Padian N, Glidden DV, Geng E. Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey. PLoS Med. 2018 Jan 12;15(1):e1002489. doi: 10.1371/journal.pmed.1002489. eCollection 2018 Jan.
• Mody A, Roy M, Sikombe K, Savory T, Holmes C, Bolton-Moore C, Padian N, Sikazwe I, Geng E. Improved Retention With 6-Month Clinic Return Intervals for Stable Human Immunodeficiency Virus-Infected Patients in Zambia. Clin Infect Dis. 2018 Jan 6;66(2):237-243. doi: 10.1093/cid/cix756.
• Mody A, Sikazwe I, Czaicki NL, Wa Mwanza M, Savory T, Sikombe K, Beres LK, Somwe P, Roy M, Pry JM, Padian N, Bolton-Moore C, Holmes CB, Geng EH. Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia. PLoS Med. 2018 Jun 5;15(6):e1002574. doi: 10.1371/journal.pmed.1002574. eCollection 2018 Jun.
• Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, Aldrovandi GM, Stringer EM, Kankasa C, Safrit JT, Stringer JS. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet. 2007 Nov 17;370(9600):1698-705. doi: 10.1016/S0140-6736(07)61605-5. Epub 2007 Nov 7.
• Geldsetzer P, Francis JM, Sando D, Asmus G, Lema IA, Mboggo E, Koda H, Lwezaula S, Ambikapathi R, Fawzi W, Ulenga N, Barnighausen T. Community delivery of antiretroviral drugs: A non-inferiority cluster-randomized pragmatic trial in Dar es Salaam, Tanzania. PLoS Med. 2018 Sep 19;15(9):e1002659. doi: 10.1371/journal.pmed.1002659. eCollection 2018 Sep.
• Mukamba N, Beres LK, Mwamba C, Law JW, Topp SM, Simbeza S, Sikombe K, Padian N, Holmes CB, Geng EH, Sikazwe I. How might improved estimates of HIV programme outcomes influence practice? A formative study of evidence, dissemination and response. Health Res Policy Syst. 2020 Oct 16;18(1):121. doi: 10.1186/s12961-020-00640-7.
• Wachira J, Middlestadt S, Reece M, Peng CY, Braitstein P. Physician communication behaviors from the perspective of adult HIV patients in Kenya. Int J Qual Health Care. 2014 Apr;26(2):190-7. doi: 10.1093/intqhc/mzu004. Epub 2014 Feb 10.
• Wachira J, Middlestadt S, Reece M, Peng CY, Braitstein P. Psychometric Assessment of a Physician-Patient Communication Behaviors Scale: The Perspective of Adult HIV Patients in Kenya. AIDS Res Treat. 2013;2013:706191. doi: 10.1155/2013/706191. Epub 2013 Feb 11.
• Bazzano AN, Martin J, Hicks E, Faughnan M, Murphy L. Human-centred design in global health: A scoping review of applications and contexts. PLoS One. 2017 Nov 1;12(11):e0186744. doi: 10.1371/journal.pone.0186744. eCollection 2017.
• Eshun-Wilson I, Kim HY, Schwartz S, Conte M, Glidden DV, Geng EH. Exploring Relative Preferences for HIV Service Features Using Discrete Choice Experiments: a Synthetic Review. Curr HIV/AIDS Rep. 2020 Oct;17(5):467-477. doi: 10.1007/s11904-020-00520-3.
• Eshun-Wilson I, Mukumbwa-Mwenechanya M, Kim HY, Zannolini A, Mwamba CP, Dowdy D, Kalunkumya E, Lumpa M, Beres LK, Roy M, Sharma A, Topp SM, Glidden DV, Padian N, Ehrenkranz P, Sikazwe I, Holmes CB, Bolton-Moore C, Geng EH. Differentiated Care Preferences of Stable Patients on Antiretroviral Therapy in Zambia: A Discrete Choice Experiment. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):540-546. doi: 10.1097/QAI.0000000000002070.
• Kruk ME, Mbaruku G, McCord CW, Moran M, Rockers PC, Galea S. Bypassing primary care facilities for childbirth: a population-based study in rural Tanzania. Health Policy Plan. 2009 Jul;24(4):279-88. doi: 10.1093/heapol/czp011. Epub 2009 Mar 20.
• Mangham LJ, Hanson K, McPake B. How to do (or not to do) ... Designing a discrete choice experiment for application in a low-income country. Health Policy Plan. 2009 Mar;24(2):151-8. doi: 10.1093/heapol/czn047. Epub 2008 Dec 26.
• Terris-Prestholt F, Hanson K, MacPhail C, Vickerman P, Rees H, Watts C. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One. 2013 Dec 30;8(12):e83193. doi: 10.1371/journal.pone.0083193. eCollection 2013.
• Bor J, Thirumurthy H. Bridging the Efficacy-Effectiveness Gap in HIV Programs: Lessons From Economics. J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3(Suppl 3):S183-S191. doi: 10.1097/QAI.0000000000002201.
• Eisinger RW, Dieffenbach CW, Fauci AS. Role of Implementation Science: Linking Fundamental Discovery Science and Innovation Science to Ending the HIV Epidemic at the Community Level. J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S171-S172. doi: 10.1097/QAI.0000000000002227.
• Geng E, Hargreaves J, Peterson M, Baral S. Implementation Research to Advance the Global HIV Response: Introduction to the JAIDS Supplement. J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S173-S175. doi: 10.1097/QAI.0000000000002208. No abstract available.
• Glidden DV, Mehrotra ML, Dunn DT, Geng EH. Mosaic effectiveness: measuring the impact of novel PrEP methods. Lancet HIV. 2019 Nov;6(11):e800-e806. doi: 10.1016/S2352-3018(19)30227-9. Epub 2019 Sep 27.
• Gomez A, Loar R, Kramer AE, Garnett GP. Reaching and targeting more effectively: the application of market segmentation to improve HIV prevention programmes. J Int AIDS Soc. 2019 Jul;22 Suppl 4(Suppl Suppl 4):e25318. doi: 10.1002/jia2.25318. No abstract available.
• Updated Recommendations on Service Delivery for the Treatment and Care of People Living with HIV [Internet]. Geneva: World Health Organization; 2021 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK570385/
• McNairy ML, Abrams EJ, Rabkin M, El-Sadr WM. Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy. PLoS Med. 2017 Apr 18;14(4):e1002278. doi: 10.1371/journal.pmed.1002278. eCollection 2017 Apr.
• El-Sadr WM, Harripersaud K, Rabkin M. Reaching global HIV/AIDS goals: What got us here, won't get us there. PLoS Med. 2017 Nov 7;14(11):e1002421. doi: 10.1371/journal.pmed.1002421. eCollection 2017 Nov.
• Geng EH, Holmes CB, Moshabela M, Sikazwe I, Petersen ML. Personalized public health: An implementation research agenda for the HIV response and beyond. PLoS Med. 2019 Dec 31;16(12):e1003020. doi: 10.1371/journal.pmed.1003020. eCollection 2019 Dec. No abstract available.
• Sikazwe I, Eshun-Wilson I, Sikombe K, Beres LK, Somwe P, Mody A, Simbeza S, Bukankala C, Glidden DV, Mulenga LB, Padian N, Ehrenkranz P, Bolton-Moore C, Holmes CB, Geng EH. Patient-reported Reasons for Stopping Care or Switching Clinics in Zambia: A Multisite, Regionally Representative Estimate Using a Multistage Sampling-based Approach in Zambia. Clin Infect Dis. 2021 Oct 5;73(7):e2294-e2302. doi: 10.1093/cid/ciaa1501.
• Hagey JM, Li X, Barr-Walker J, Penner J, Kadima J, Oyaro P, Cohen CR. Differentiated HIV care in sub-Saharan Africa: a scoping review to inform antiretroviral therapy provision for stable HIV-infected individuals in Kenya. AIDS Care. 2018 Dec;30(12):1477-1487. doi: 10.1080/09540121.2018.1500995. Epub 2018 Jul 23.
• Grimsrud A, Barnabas RV, Ehrenkranz P, Ford N. Evidence for scale up: the differentiated care research agenda. J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024. doi: 10.7448/IAS.20.5.22024. No abstract available.
• Grimsrud A, Bygrave H, Doherty M, Ehrenkranz P, Ellman T, Ferris R, Ford N, Killingo B, Mabote L, Mansell T, Reinisch A, Zulu I, Bekker LG. Reimagining HIV service delivery: the role of differentiated care from prevention to suppression. J Int AIDS Soc. 2016 Dec 1;19(1):21484. doi: 10.7448/IAS.19.1.21484. eCollection 2016. No abstract available.
• Topp SM, Mwamba C, Sharma A, Mukamba N, Beres LK, Geng E, Holmes CB, Sikazwe I. Rethinking retention: Mapping interactions between multiple factors that influence long-term engagement in HIV care. PLoS One. 2018 Mar 14;13(3):e0193641. doi: 10.1371/journal.pone.0193641. eCollection 2018.
• Larson E, Vail D, Mbaruku GM, Kimweri A, Freedman LP, Kruk ME. Moving Toward Patient-Centered Care in Africa: A Discrete Choice Experiment of Preferences for Delivery Care among 3,003 Tanzanian Women. PLoS One. 2015 Aug 11;10(8):e0135621. doi: 10.1371/journal.pone.0135621. eCollection 2015.
• Chamberlin S, Mphande M, Phiri K, Kalande P, Dovel K. How HIV Clients Find Their Way Back to the ART Clinic: A Qualitative Study of Disengagement and Re-engagement with HIV Care in Malawi. AIDS Behav. 2022 Mar;26(3):674-685. doi: 10.1007/s10461-021-03427-1. Epub 2021 Aug 17.
• Chimbindi N, Barnighausen T, Newell ML. Patient satisfaction with HIV and TB treatment in a public programme in rural KwaZulu-Natal: evidence from patient-exit interviews. BMC Health Serv Res. 2014 Jan 23;14:32. doi: 10.1186/1472-6963-14-32.
• Peltzer K. Patient experiences and health system responsiveness in South Africa. BMC Health Serv Res. 2009 Jul 14;9:117. doi: 10.1186/1472-6963-9-117.
• Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, Muyindike W, Bwana MB, Yiannoutsos CT, Petersen ML, Martin JN. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010 Nov;7(4):234-44. doi: 10.1007/s11904-010-0061-5.
• Mody A, Glidden DV, Eshun-Wilson I, Sikombe K, Simbeza S, Mukamba N, Somwe P, Beres LK, Pry J, Bolton-Moore C, Padian N, Holmes CB, Sikazwe I, Geng EH. Longitudinal Care Cascade Outcomes Among People Eligible for Antiretroviral Therapy Who Are Newly Linking to Care in Zambia: A Multistate Analysis. Clin Infect Dis. 2020 Dec 17;71(10):e561-e570. doi: 10.1093/cid/ciaa268.
• Mwamba C, Sharma A, Mukamba N, Beres L, Geng E, Holmes CB, Sikazwe I, Topp SM. 'They care rudely!': resourcing and relational health system factors that influence retention in care for people living with HIV in Zambia. BMJ Glob Health. 2018 Oct 25;3(5):e001007. doi: 10.1136/bmjgh-2018-001007. eCollection 2018.
• Fox MP, Bor J, Brennan AT, MacLeod WB, Maskew M, Stevens WS, Carmona S. Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa. PLoS Med. 2018 Jun 11;15(6):e1002589. doi: 10.1371/journal.pmed.1002589. eCollection 2018 Jun.
• Taieb F, Madec Y, Cournil A, Delaporte E. Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis. PLoS One. 2017 Apr 20;12(4):e0174767. doi: 10.1371/journal.pone.0174767. eCollection 2017.
• Justman JE, Mugurungi O, El-Sadr WM. HIV Population Surveys - Bringing Precision to the Global Response. N Engl J Med. 2018 May 17;378(20):1859-1861. doi: 10.1056/NEJMp1801934. No abstract available.
• Dopp AR, Parisi KE, Munson SA, Lyon AR. Integrating implementation and user-centred design strategies to enhance the impact of health services: protocol from a concept mapping study. Health Res Policy Syst. 2019 Jan 8;17(1):1. doi: 10.1186/s12961-018-0403-0.
• Mukumbang FC, Mwale JC, van Wyk B. Conceptualising the Factors Affecting Retention in Care of Patients on Antiretroviral Treatment in Kabwe District, Zambia, Using the Ecological Framework. AIDS Res Treat. 2017;2017:7356362. doi: 10.1155/2017/7356362. Epub 2017 Nov 9.
• Camlin CS, Neilands TB, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi EA, Glidden DV, Wools-Kaloustian KK, Wenger M, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. Patient-reported factors associated with reengagement among HIV-infected patients disengaged from care in East Africa. AIDS. 2016 Jan 28;30(3):495-502. doi: 10.1097/QAD.0000000000000931.
• TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016 May;16(5):565-575. doi: 10.1016/S1473-3099(15)00536-8. Epub 2016 Jan 29.
• Glass TR, Motaboli L, Nsakala B, Lerotholi M, Vanobberghen F, Amstutz A, Lejone TI, Muhairwe J, Klimkait T, Labhardt ND. The viral load monitoring cascade in a resource-limited setting: A prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho. PLoS One. 2019 Aug 28;14(8):e0220337. doi: 10.1371/journal.pone.0220337. eCollection 2019.
• Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis. J Int AIDS Soc. 2019 Nov;22(11):e25415. doi: 10.1002/jia2.25415.
• Hermans LE, Carmona S, Nijhuis M, Tempelman HA, Richman DD, Moorhouse M, Grobbee DE, Venter WDF, Wensing AMJ. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study. PLoS Med. 2020 Feb 25;17(2):e1003037. doi: 10.1371/journal.pmed.1003037. eCollection 2020 Feb.
• Sikombe K, Mody A, Kadota J, Pry JJ, Simbeza S, Eshun-Wilson I, Situmbeko SR, Bukankala C, Beres L, Mukamba N, Wa Mwanza M, Bolton-Moore C, Holmes CB, Geng EH, Sikazwe I. Understanding patient transfers across multiple clinics in Zambia among HIV infected adults. PLoS One. 2020 Nov 4;15(11):e0241477. doi: 10.1371/journal.pone.0241477. eCollection 2020.
• Eshun-Wilson I, Rohwer A, Hendricks L, Oliver S, Garner P. Being HIV positive and staying on antiretroviral therapy in Africa: A qualitative systematic review and theoretical model. PLoS One. 2019 Jan 10;14(1):e0210408. doi: 10.1371/journal.pone.0210408. eCollection 2019.
• Zanolini A, Sikombe K, Sikazwe I, Eshun-Wilson I, Somwe P, Bolton Moore C, Topp SM, Czaicki N, Beres LK, Mwamba CP, Padian N, Holmes CB, Geng EH. Understanding preferences for HIV care and treatment in Zambia: Evidence from a discrete choice experiment among patients who have been lost to follow-up. PLoS Med. 2018 Aug 13;15(8):e1002636. doi: 10.1371/journal.pmed.1002636. eCollection 2018 Aug.
• Ware NC, Wyatt MA, Geng EH, Kaaya SF, Agbaji OO, Muyindike WR, Chalamilla G, Agaba PA. Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study. PLoS Med. 2013;10(1):e1001369; discussion e1001369. doi: 10.1371/journal.pmed.1001369. Epub 2013 Jan 8.
• Hickey MD, Omollo D, Salmen CR, Mattah B, Blat C, Ouma GB, Fiorella KJ, Njoroge B, Gandhi M, Bukusi EA, Cohen CR, Geng EH. Movement between facilities for HIV care among a mobile population in Kenya: transfer, loss to follow-up, and reengagement. AIDS Care. 2016 Nov;28(11):1386-93. doi: 10.1080/09540121.2016.1179253. Epub 2016 May 4.
• Balde A, Lievre L, Maiga AI, Diallo F, Maiga IA, Costagliola D, Abgrall S. Re-engagement in care of people living with HIV lost to follow-up after initiation of antiretroviral therapy in Mali: Who returns to care? PLoS One. 2020 Sep 10;15(9):e0238687. doi: 10.1371/journal.pone.0238687. eCollection 2020.
• Mirzazadeh A, Eshun-Wilson I, Thompson RR, Bonyani A, Kahn JG, Baral SD, Schwartz S, Rutherford G, Geng EH. Interventions to reengage people living with HIV who are lost to follow-up from HIV treatment programs: A systematic review and meta-analysis. PLoS Med. 2022 Mar 15;19(3):e1003940. doi: 10.1371/journal.pmed.1003940. eCollection 2022 Mar.
• Bershetyn A, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Hartogensis W, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium. The Causal Effect of Tracing by Peer Health Workers on Return to Clinic Among Patients Who Were Lost to Follow-up From Antiretroviral Therapy in Eastern Africa: A "Natural Experiment" Arising From Surveillance of Lost Patients. Clin Infect Dis. 2017 Jun 1;64(11):1547-1554. doi: 10.1093/cid/cix191.
• Mody A, Sikombe K, Beres LK, Simbeza S, Mukamba N, Eshun-Wilson I, Schwartz S, Pry J, Padian N, Holmes CB, Bolton-Moore C, Sikazwe I, Geng EH. Profiles of HIV Care Disruptions Among Adult Patients Lost to Follow-up in Zambia: A Latent Class Analysis. J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):62-72. doi: 10.1097/QAI.0000000000002530.
• Ardura-Garcia C, Feldacker C, Tweya H, Chaweza T, Kalulu M, Phiri S, Wang D, Weigel R. Implementation and Operational Research: Early Tracing of Children Lost to Follow-Up From Antiretroviral Treatment: True Outcomes and Future Risks. J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e160-7. doi: 10.1097/QAI.0000000000000772.
• Teklu AM, Yirdaw KD. Patients who restart antiretroviral medication after interruption remain at high risk of unfavorable outcomes in Ethiopia. BMC Health Serv Res. 2017 Apr 4;17(1):247. doi: 10.1186/s12913-017-2172-9.
• Nakiwogga-Muwanga A, Musaazi J, Katabira E, Worodria W, Talisuna SA, Colebunders R. Patients who return to care after tracking remain at high risk of attrition: experience from a large HIV clinic, Uganda. Int J STD AIDS. 2015 Jan;26(1):42-7. doi: 10.1177/0956462414529098. Epub 2014 Mar 19.
• Mugavero MJ, Westfall AO, Cole SR, Geng EH, Crane HM, Kitahata MM, Mathews WC, Napravnik S, Eron JJ, Moore RD, Keruly JC, Mayer KH, Giordano TP, Raper JL; Centers for AIDS Research Network of Integrated Clinical Systems (CNICS). Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality. Clin Infect Dis. 2014 Nov 15;59(10):1471-9. doi: 10.1093/cid/ciu603. Epub 2014 Aug 4.
• Geng EH, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Wenger M, Neilands TB, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J. Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach. Clin Infect Dis. 2016 Apr 1;62(7):935-944. doi: 10.1093/cid/civ1004. Epub 2015 Dec 17.
• Mody A, Eshun-Wilson I, Sikombe K, Schwartz SR, Beres LK, Simbeza S, Mukamba N, Somwe P, Bolton-Moore C, Padian N, Holmes CB, Sikazwe I, Geng EH. Longitudinal engagement trajectories and risk of death among new ART starters in Zambia: A group-based multi-trajectory analysis. PLoS Med. 2019 Oct 29;16(10):e1002959. doi: 10.1371/journal.pmed.1002959. eCollection 2019 Oct.
• Chammartin F, Zurcher K, Keiser O, Weigel R, Chu K, Kiragga AN, Ardura-Garcia C, Anderegg N, Laurent C, Cornell M, Tweya H, Haas AD, Rice BD, Geng EH, Fox MP, Hargreaves JR, Egger M. Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis. Clin Infect Dis. 2018 Nov 13;67(11):1643-1652. doi: 10.1093/cid/ciy347.
• Colasanti J, Kelly J, Pennisi E, Hu YJ, Root C, Hughes D, Del Rio C, Armstrong WS. Continuous Retention and Viral Suppression Provide Further Insights Into the HIV Care Continuum Compared to the Cross-sectional HIV Care Cascade. Clin Infect Dis. 2016 Mar 1;62(5):648-654. doi: 10.1093/cid/civ941. Epub 2015 Nov 12.
• Haber N, Tanser F, Bor J, Naidu K, Mutevedzi T, Herbst K, Porter K, Pillay D, Barnighausen T. From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. Lancet HIV. 2017 May;4(5):e223-e230. doi: 10.1016/S2352-3018(16)30224-7. Epub 2017 Jan 31.
• Hallett TB, Eaton JW. A side door into care cascade for HIV-infected patients? J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S228-32. doi: 10.1097/QAI.0b013e318298721b.
• Grimsrud A, Wilkinson L, Eshun-Wilson I, Holmes C, Sikazwe I, Katz IT. Understanding Engagement in HIV Programmes: How Health Services Can Adapt to Ensure No One Is Left Behind. Curr HIV/AIDS Rep. 2020 Oct;17(5):458-466. doi: 10.1007/s11904-020-00522-1.
• Billong SC, Fokam J, Penda CI, Amadou S, Kob DS, Billong EJ, Colizzi V, Ndjolo A, Bisseck AZ, Elat JN. Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling. BMC Infect Dis. 2016 Nov 15;16(1):678. doi: 10.1186/s12879-016-1991-3.
• Sikazwe I, Eshun-Wilson I, Sikombe K, Czaicki N, Somwe P, Mody A, Simbeza S, Glidden DV, Chizema E, Mulenga LB, Padian N, Duncombe CJ, Bolton-Moore C, Beres LK, Holmes CB, Geng E. Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approach. PLoS Med. 2019 May 31;16(5):e1002811. doi: 10.1371/journal.pmed.1002811. eCollection 2019 May.
• Beres LK, Schwartz S, Simbeza S, McGready J, Eshun-Wilson I, Mwamba C, Sikombe K, Topp SM, Somwe P, Mody A, Mukamba N, Ehrenkranz PD, Padian N, Pry J, Moore CB, Holmes CB, Sikazwe I, Denison JA, Geng E. Patterns and Predictors of Incident Return to HIV Care Among Traced, Disengaged Patients in Zambia: Analysis of a Prospective Cohort. J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):313-322. doi: 10.1097/QAI.0000000000002554.
• Scholl I, Zill JM, Harter M, Dirmaier J. An integrative model of patient-centeredness - a systematic review and concept analysis. PLoS One. 2014 Sep 17;9(9):e107828. doi: 10.1371/journal.pone.0107828. eCollection 2014.
• Geng EH, Glidden DV, Bwana MB, Musinguzi N, Emenyonu N, Muyindike W, Christopoulos KA, Neilands TB, Yiannoutsos CT, Deeks SG, Bangsberg DR, Martin JN. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One. 2011;6(7):e21797. doi: 10.1371/journal.pone.0021797. Epub 2011 Jul 26.

Study record dates

Study Major Dates

• Study Start (Actual): August 10, 2022
• Primary Completion (Actual): July 31, 2025
• Study Completion (Actual): July 31, 2025

Study Registration Dates

• First Submitted: January 27, 2025
• First Submitted That Met QC Criteria: January 27, 2025
• First Posted (Actual): January 31, 2025

Study Record Updates

• Last Update Posted (Actual): August 12, 2026
• Last Update Submitted That Met QC Criteria: August 10, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Keywords: HIV; Retention; Antiretroviral Therapy (ART); Reengagement
• Other Study ID Numbers: REENGAGEMENT (R34); 1R34MH129219-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Data will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Once data are linked to SmartCare records using ART numbers, identifying information will be removed in order to maintain confidentiality. Similarly, transcriptions will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis.
• IPD Sharing Time Frame: 2022 - 2025
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No